What Calm Treats: Main Uses and Benefits

Calm (Clobazam) is commonly used as adjunctive therapy for seizures associated with severe conditions like Lennox-Gastaut syndrome (LGS). Use is relevant for pediatric and adult patient groups. The therapeutic scope is focused on providing supportive relief where symptoms create noticeable physiological strain.

The medication may be applied across therapeutic domains involving seizure control and is relevant in situations requiring short-term symptomatic assistance for severe heightened anxiety and acute agitation.

This medicine may help address symptom clusters that may become intense or disruptive, including sudden drop seizures, other pronounced motor disturbances, and emotional tension. This provides support that helps ease the overall symptom burden associated with disruptive episodic manifestations.

“The primary goal is providing support that helps ease the overall symptom burden associated with disruptive episodic manifestations.”

Quick Fact: Relief for Debilitating Seizure Clusters Calm is relevant for managing symptoms that interfere with daily comfort, such as sudden drop seizures and other motor disturbances, assisting with maintaining functional stability during symptomatic periods.

Regulatory References

1. NIH Medical Genetics Summaries overview

Official Eligibility Profile for Calm (Clobazam)

Calm is officially allowed for use in adults and pediatric patients 2 years of age and older for its primary seizure indication, as documented by regulatory agencies. Use is not established in children younger than 2 years.

---

Populations For Whom Use is Contraindicated

Use of Clobazam is absolutely prohibited (contraindicated) for individuals with a history of hypersensitivity to Clobazam, other benzodiazepines, or any of the product's ingredients. Regulatory documents also cite contraindications for patients with severe hepatic insufficiency and those with conditions that severely compromise breathing, such as severe respiratory insufficiency or severe sleep apnea syndrome.

---

Restricted and Conditional Use

• Older Adults (Geriatric): Use requires caution, and a reduced starting dose is mandated due to increased sensitivity to adverse effects.
• Organ Function: Patients with mild or moderate hepatic impairment or renal impairment require caution, often necessitating dose adjustment due to impaired drug clearance.
• Reproductive Status: Clobazam is not recommended for use in breastfeeding women due to excretion into breast milk. Use during pregnancy is generally not recommended, especially late in gestation, due to potential risks to the neonate.
• History: Caution and strict monitoring are required for patients with a history of drug or alcohol dependence due to the potential for abuse and physical dependence.

Interactions with other medicines and products

This medication contains an active ingredient (e.g., a sedating antihistamine or a skeletal muscle relaxant) with established interactions based on official labeling. The primary concern is additive central nervous system (CNS) and anticholinergic effects.

---

High-Risk Combinations (Major/Contraindicated)

Interacting Product Category	Potential Effect	Restriction
CNS Depressants (including Alcohol, sedatives, tranquilizers, opioids)	Profound sedation, respiratory depression, coma, and death.	Avoid concurrent use; consult a healthcare provider.
MAO Inhibitors (e.g., phenelzine, tranylcypromine, isocarboxazid, linezolid)	Prolonged and intensified anticholinergic effects; CNS excitation/depression.	Contraindicated. Do not use within 14 days of stopping an MAOI.

---

Other Noteworthy Interactions

Concomitant use with other Anticholinergic Agents (e.g., tricyclic antidepressants, certain antispasmodics) may result in additive adverse effects such as dry mouth, blurred vision, constipation, and difficulty with urination. Care must be taken to check for this ingredient in other products, including those used on the skin, to avoid exceeding safe levels or compounding effects. Patients with underlying conditions like glaucoma or prostate enlargement are at increased risk for complications from anticholinergic interactions.

The mechanism of action involves the synergistic activity of its primary components, magnesium and L-theanine, targeting central nervous system neurotransmission and cellular energy regulation.

Magnesium acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated ion channel. This interaction modifies the excitatory glutamatergic signaling cascade. Concurrently, magnesium functions as an allosteric modulator of the gamma-aminobutyric acid ( GABAA) receptor, enhancing the binding and inhibitory actions of the neurotransmitter GABA. Intracellularly, magnesium is an essential cofactor for numerous enzymes, including those governing the synthesis and utilization of adenosine triphosphate (ATP), impacting neuronal and muscular bioenergetics. System-level physiological consequences include modulation of the hypothalamic-pituitary-adrenal (HPA) axis and altered skeletal muscle contractility.

L-theanine crosses the blood-brain barrier and structurally resembles glutamate, acting as a weak competitive antagonist at its receptors. Crucially, L-theanine promotes the synthesis and release of the inhibitory neurotransmitter GABA in specific brain regions. Downstream, this GABAergic potentiation increases alpha brain wave activity, which is an electrophysiological signature associated with a less reactive cortical state. Additionally, L-theanine influences monoamine levels, including dopamine and serotonin, by mechanisms that are currently understood to be indirect. This combined molecular modulation contributes to systemic neurophysiological quietude and diminished motor unit excitability.

How to Use Calm (Clobazam)

Clobazam is administered orally in multiple dosage forms, including tablets, an oral suspension (liquid form), and an oral film. For most formulations, administration may occur with or without food.

---

Dosing and Frequency Principles

Standard adult regimens for adjunctive seizure treatment typically start at 10 mg daily. Doses greater than 5 mg daily are generally administered in divided doses (twice daily), and larger portions are often taken at night. Dosage adjustments, or titration, must proceed slowly, no faster than weekly, to reach the designated maximum daily dose of 40 mg.

---

Administration and Duration

When using the oral suspension, the bottle must be shaken well before each measurement, and the specific dosing syringe provided should be used. Tablets may be crushed and mixed with soft food like applesauce, but oral films must be allowed to dissolve entirely on top of the tongue without being chewed or swallowed whole.

Specific lower starting doses of 5 mg and lower maximum doses are designated for older adults, individuals with mild to moderate hepatic impairment, and those identified as CYP2C19 poor metabolizers.

For anxiety treatment, use is limited to a short-term duration, often not exceeding four weeks. Upon cessation, the medicine requires a gradual withdrawal (tapering) by decreasing the dose weekly over time.

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research has examined the study drug for use in individuals with Chronic Migraine (CM) who had not responded adequately to first-line treatments. The research investigated a medication that acts on the calcitonin gene-related peptide (CGRP) pathway.

Studies have evaluated whether the combination of treatment X and Y shows different outcomes compared to monotherapy to measure differences in attack frequency and severity. Initial research primarily focused on measuring the change in the average number of monthly migraine days (MMDs) over a 3-month period.

---

Key Efficacy Endpoints

Reduction in Monthly Migraine Days (MMDs)

• Core Measure: The primary endpoint in most pivotal trials was the change from baseline in MMDs over 12 weeks.
• Observations: A phase 3 trial involving 840 participants with CM reported a mean reduction of 4.5 MMDs in the group receiving the study medication, compared to a reduction of 2.1 MMDs in the placebo group (p < 0.001).

Impact on Quality of Life and Disability

Research also explored the impact of the treatment on patient-reported outcomes, specifically using the Migraine-Specific Quality of Life Questionnaire (MSQ) and the Migraine Disability Assessment Scale (MIDAS).

• Findings: Trial data suggested that individuals receiving the treatment experienced different scores on the MSQ Role Function domain compared to placebo recipients. The medication's potential effect on pain was explored in these trials.

---

Safety and Tolerability Profiles

Research has explored the potential of this treatment for long-term use, and monitoring of liver function was included in the study protocols.

• Reported Adverse Events: The most frequently reported adverse events (occurring in more than 5% of participants) included injection site reactions, constipation, and muscle cramps. Most reported events were categorized by the investigators as mild to moderate.
• Discontinuation Rates: Discontinuation of treatment due to adverse events was reported in 2.5% of the active treatment group compared to 1.5% in the placebo group. The difference in discontinuation rates was small between the active treatment group (2.5%) and the placebo group (1.5%).

Evidence remains limited regarding the treatment's role in episodic migraine.

Key Studies & References

1. Erenumab for the prevention of chronic migraine: safety and efficacy results from a randomized, double-blind, placebo-controlled, phase 3 trial (REGAIN)
2. CGRP-Targeted Monoclonal Antibodies for Migraine Prevention: A Narrative Review of Efficacy, Safety, and Tolerability

Common questions about Calm (FAQ)

---

Q: How quickly does Calm start to work after I take it?

Official information regarding the drug's activity indicates that the active ingredient and its primary active metabolite take several days to build up in the body. Specifically, the substance requires 5 to 9 days to reach a stable, steady-state concentration in the bloodstream. Noticeable effects may not be immediate.

---

Q: How long does the effect of Calm usually last?

Studies on the drug's properties indicate that both the primary active ingredient and its active metabolite have long half-lives, meaning they remain present in the body for an extended period. This long-acting nature is noted in the drug's properties.

---

Q: Does Calm cause people to feel sleepy or drowsy?

Yes, regulatory documents list somnolence (a medical term for sleepiness or drowsiness) and sedation as very common side effects observed during clinical trials. In some studies, up to 32% of patients reported experiencing somnolence. Given these reports, caution regarding potential drowsiness is generally noted during initiation.

---

Q: Are there any common foods or drinks that interact with Calm?

Official drug interaction warnings state that concurrent use with alcohol is noted because it can significantly increase the drug's levels in the blood, potentially leading to severe drowsiness and breathing problems. Beyond alcohol, there are no other specific common foods or drinks listed in the official product information as known to cause problematic interactions.

---

Q: Does Calm have a risk of dependence or withdrawal?

The use of this type of medicine is associated with a risk of developing physical dependence. If the medication is stopped suddenly or the dosage is reduced too quickly, it can precipitate acute withdrawal reactions, which are noted as potentially severe. Official instructions address the need for gradual reduction (tapering) if the medicine is to be stopped.

---

Q: Is Calm a controlled substance?

Yes, official regulatory documents classify the medicine as a Schedule IV federally controlled substance. This classification is due to its associated risk for abuse, misuse, and potential addiction.

---

Q: Will I be able to drive a car while taking Calm?

The official Medication Guide states that this medication can make you drowsy and affect your thinking, ability to make decisions, and coordination. The guide recommends caution and avoidance of driving or operating dangerous machinery until the medication’s effect on the individual is known.

---

Q: How long can a person safely stay on Calm?

For its primary indication, the medicine is often used as adjunctive therapy for an extended period. However, regulatory documents indicate that the risk of physical dependence and withdrawal increases with longer treatment duration. The determination of treatment duration is a decision based on clinical assessment.

---

Q: Is it normal for the effects of Calm to feel weaker over time?

Official reports sometimes list drug tolerance as a possible side effect for this class of medication. Tolerance means the body may get used to the medicine over time, causing the drug’s effects to lessen. Although tolerance may occur, the treatment response may be maintained in many patients on long-term therapy.

---

Q: Are there different strengths or versions of Calm available?

According to official regulatory sources, the tablets are available in different strengths, as well as in other formulations like the oral suspension and oral film.

---

Q: Are allergic reactions to Calm common?

Official warnings and precautions mention the potential for rare but very serious skin reactions, such as Stevens-Johnson Syndrome (SJS), which require immediate attention. Official labels do not typically provide a common or uncommon frequency for general, non-severe allergic reactions like a mild rash.

---

Q: What is the general safety classification of Calm by regulatory bodies?

Regulatory bodies classify this medicine as a Schedule IV controlled substance. Its use during pregnancy also carries a warning about potential risks for the neonate, including sedation and withdrawal syndrome.

---

Q: What if I experience a side effect not listed in the standard information?

Official regulatory guidance notes that contacting a healthcare provider immediately or utilizing reporting programs, such as the FDA MedWatch program, is appropriate for unlisted side effects.

How to Store and Dispose of Clobazam (Calm)

Clobazam must be stored according to regulatory requirements to ensure its stability. The medicine should be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and kept in its original, tightly closed container. The oral suspension form has a specific stability rule and must not be frozen; any unused portion must be discarded after 90 days from the date the bottle was first opened. As a mandatory safety measure, the medicine must be stored in a secure location, out of the sight and reach of children.

Disposal of unused or expired Clobazam should prioritize an official drug take-back program. If a take-back program is unavailable, the medicine must be mixed with an undesirable substance (such as used coffee grounds or dirt) and placed into a sealed container before being thrown in the household trash.